Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 111 articles: HTML format Text format

Single Articles

May 2018
1. MEDER L, Schuldt P, Thelen M, Schmitt A, et al
   Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer.
   Cancer Res. 2018 May 18. pii: 0008-5472.CAN-17-2176.
   PubMed     Text format     Abstract available
   
   
   April 2018
2. HEIM L, Friedrich J, Engelhardt M, Trufa DI, et al
   NFATc1 promotes anti-tumoral effector functions and memory CD8+ T cell differentiation during non-small cell lung cancer development.
   Cancer Res. 2018 Apr 24. pii: 0008-5472.CAN-17-3297.
   PubMed     Text format     Abstract available
   
   
   
3. SU W, Feng S, Chen X, Yang X, et al
   Silencing of long non-coding RNA MIR22HG triggers cell survival/death signaling via oncogenes YBX1, MET, and p21 in lung cancer.
   Cancer Res. 2018 Apr 18. pii: 0008-5472.CAN-18-0222.
   PubMed     Text format     Abstract available
   
   
   February 2018
4. MAKINOSHIMA H, Umemura S, Suzuki A, Nakanishi H, et al
   Metabolic determinants of sensitivity to phosphatidylinositol 3-kinase pathway inhibitor in small-cell lung carcinoma.
   Cancer Res. 2018 Feb 28. pii: 0008-5472.CAN-17-2109.
   PubMed     Text format     Abstract available
   
   
   
5. DE S, Lindner DJ, Coleman C, Wildey G, et al
   The FACT inhibitor CBL0137 synergizes with cisplatin in small cell lung cancer by increasing NOTCH1 expression and targeting tumor-initiating cells.
   Cancer Res. 2018 Feb 13. pii: 0008-5472.CAN-17-1920.
   PubMed     Text format     Abstract available
   
   
   January 2018
6. CARONNI N, Simoncello F, Stafetta F, Guarnaccia C, et al
   Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer.
   Cancer Res. 2018 Jan 23. pii: 0008-5472.CAN-17-1307.
   PubMed     Text format     Abstract available
   
   
   
7. DOPESO H, Jiao HK, Cuesta AM, Henze AT, et al
   PHD3 controls lung cancer metastasis and resistance to EGFR inhibitors through TGFalpha.
   Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-1346.
   PubMed     Text format     Abstract available
   
   
   December 2017
8. ADELAIYE-OGALA R, Budka J, Damayanti NP, Arrington J, et al
   EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
   Cancer Res. 2017;77:6651-6666.
   PubMed     Text format     Abstract available
   
   
   November 2017
9. EMERSON MA, Banegas MP, Chawla N, Achacoso N, et al
   Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
   Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0429.
   PubMed     Text format     Abstract available
   
   
   
10. SIVAKUMAR S, Lucas FAS, McDowell TL, Lang W, et al
    Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.
    Cancer Res. 2017;77:6119-6130.
    PubMed     Text format     Abstract available
    
    
    
11. KWAK JW, Laskowski J, Li HY, McSharry MV, et al
    Complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression.
    Cancer Res. 2017 Nov 8. pii: canres.0240.2017.
    PubMed     Text format     Abstract available
    
    
    
12. WANG W, Huang L, Jin JY, Jolly S, et al
    IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.
    Cancer Res. 2017 Nov 8. pii: canres.2995.2017.
    PubMed     Text format     Abstract available
    
    
    
13. HUANG H, Zhang W, Pan Y, Gao Y, et al
    YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation.
    Cancer Res. 2017;77:5769-5781.
    PubMed     Text format     Abstract available
    
    
    October 2017
14. ZUO H, Ueland PM, Midttun O, Vollset SE, et al
    Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) link vitamin B6 catabolism and lung cancer risk.
    Cancer Res. 2017 Oct 25. pii: canres.1923.2017.
    PubMed     Text format     Abstract available
    
    
    September 2017
15. KIDDER BL, He R, Wangsa D, Padilla-Nash HM, et al
    SMYD5 controls heterochromatin and chromosome integrity during embryonic stem cell differentiation.
    Cancer Res. 2017 Sep 26. pii: canres.0828.2017.
    PubMed     Text format     Abstract available
    
    
    
16. SHUKLA V, Rao M, Zhang H, Beers J, et al
    ASXL3 is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.
    Cancer Res. 2017 Sep 21. pii: canres.0570.2017.
    PubMed     Text format     Abstract available
    
    
    
17. YAO M, Yu T, Zhao YJ, Hu Z, et al
    MetaLnc9 facilitates lung cancer metastasis via a PGK1-activated AKT/mTOR pathway.
    Cancer Res. 2017 Sep 18. pii: canres.0671.2017.
    PubMed     Text format     Abstract available
    
    
    
18. LIU Y, Li Y, Wang X, Liu F, et al
    Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
    Cancer Res. 2017;77:5068-5076.
    PubMed     Text format     Abstract available
    
    
    
19. MURLIDHAR V, Reddy RM, Fouladdel S, Zhao L, et al
    Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers.
    Cancer Res. 2017;77:5194-5206.
    PubMed     Text format     Abstract available
    
    
    
20. MCFARLAND CD, Yaglom JA, Wojtkowiak JW, Scott JG, et al
    The Damaging Effect of Passenger Mutations on Cancer Progression.
    Cancer Res. 2017;77:4763-4772.
    PubMed     Text format     Abstract available
    
    
    
21. KACHLER K, Bailer M, Heim L, Schumacher F, et al
    Enhanced acid sphingomyelinase activity drives immune evasion and tumor growth in non-small cell lung carcinoma.
    Cancer Res. 2017 Sep 7. pii: canres.3313.2016.
    PubMed     Text format     Abstract available
    
    
    
22. TAKAGI S, Ishikawa Y, Mizutani A, Iwasaki S, et al
    LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
    Cancer Res. 2017;77:4652-4662.
    PubMed     Text format     Abstract available
    
    
    August 2017
23. KASIRI S, Shao C, Chen B, Wilson AN, et al
    GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.
    Cancer Res. 2017;77:4448-4459.
    PubMed     Text format     Abstract available
    
    
    July 2017
24. TILL J, Yoon C, Kim BJ, Roby KC, et al
    Oncogenic KRAS and p53 loss drive gastric tumorigenesis in mice that can be attenuated by E-cadherin expression.
    Cancer Res. 2017 Jul 31. pii: canres.0061.2017.
    PubMed     Text format     Abstract available
    
    
    
25. DU W, Xu X, Niu Q, Zhang X, et al
    Spi-B-mediated silencing of Claudin-2 promotes early dissemination of lung cancer cells from primary tumors.
    Cancer Res. 2017 Jul 28. pii: canres.0020.2017.
    PubMed     Text format     Abstract available
    
    
    
26. SALVADOR F, Martin A, Lopez-Menendez C, Moreno-Bueno G, et al
    Lysyl oxidase-like protein LOXL2 promotes lung metastasis of breast cancer.
    Cancer Res. 2017 Jul 18. pii: canres.3152.2016.
    PubMed     Text format     Abstract available
    
    
    
27. COOPER JM, Ou YH, McMillan E, Vaden RM, et al
    TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer.
    Cancer Res. 2017 Jul 17. pii: canres.0829.2017.
    PubMed     Text format     Abstract available
    
    
    
28. JERMYN M, Mercier J, Aubertin K, Desroches J, et al
    Highly Accurate Detection of Cancer In Situ with Intraoperative, Label-Free, Multimodal Optical Spectroscopy.
    Cancer Res. 2017;77:3942-3950.
    PubMed     Text format     Abstract available
    
    
    
29. JIANG H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, et al
    Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
    Cancer Res. 2017;77:3894-3907.
    PubMed     Text format     Abstract available
    
    
    
30. CHAKRABARTI S, Michor F
    Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution.
    Cancer Res. 2017;77:3908-3921.
    PubMed     Text format     Abstract available
    
    
    
31. NG KY, Chan LH, Chai S, Tong M, et al
    TP53INP1 down-regulation activates a p73-dependent DUSP10/ERK signaling pathway to promote metastasis of hepatocellular carcinoma.
    Cancer Res. 2017 Jul 3. pii: canres.3456.2016.
    PubMed     Text format     Abstract available
    
    
    June 2017
32. RICHER AL, Cala JM, O'Brien K, Carson VM, et al
    WEE1 kinase inhibitor AZD1775 has pre-clinical efficacy in LKB1-deficient non-small cell lung cancer.
    Cancer Res. 2017 Jun 26. pii: canres.3565.2016.
    PubMed     Text format     Abstract available
    
    
    
33. YOUNG A, Ngiow SF, Madore J, Reinhardt J, et al
    Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis.
    Cancer Res. 2017 Jun 26. pii: canres.0393.2017.
    PubMed     Text format     Abstract available
    
    
    
34. TRIPATHI SC, Fahrmann JF, Celiktas M, Aguilar M, et al
    MCAM mediates chemoresistance in small cell lung cancer via the PI3K/AKT/SOX2 signaling pathway.
    Cancer Res. 2017 Jun 23. pii: canres.2874.2016.
    PubMed     Text format     Abstract available
    
    
    May 2017
35. RIOS VELAZQUEZ E, Parmar C, Liu Y, Coroller TP, et al
    Somatic mutations drive distinct imaging phenotypes in lung cancer.
    Cancer Res. 2017 May 31. pii: canres.0122.2017.
    PubMed     Text format     Abstract available
    
    
    
36. YE M, Zhang Y, Zhang X, Zhang JB, et al
    Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer.
    Cancer Res. 2017 May 18. pii: canres.3470.2016.
    PubMed     Text format     Abstract available
    
    
    
37. SEN T, Tong P, Stewart CA, Cristea S, et al
    CHK1 inhibition in small cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib.
    Cancer Res. 2017 May 10. pii: canres.3409.2016.
    PubMed     Text format     Abstract available
    
    
    
38. PRAT A, Navarro A, Pare L, Reguart N, et al
    Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma.
    Cancer Res. 2017 May 9. pii: canres.3556.2017.
    PubMed     Text format     Abstract available
    
    
    
39. SHARMA SK, Pourat J, Abdel-Atti D, Carlin SD, et al
    Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
    Cancer Res. 2017 May 9. pii: canres.0299.2017.
    PubMed     Text format     Abstract available
    
    
    
40. PAILLER E, Oulhen M, Borget I, Remon J, et al
    Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.
    Cancer Res. 2017;77:2222-2230.
    PubMed     Text format     Abstract available
    
    
    April 2017
41. ICHIHARA E, Westover D, Meador CB, Yan Y, et al
    SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer.
    Cancer Res. 2017 Apr 17. pii: canres.2300.2016.
    PubMed     Text format     Abstract available
    
    
    
42. ZHANG Y, Xu W, Guo H, Zhang Y, et al
    NOTCH1 Signaling Regulates Self-renewal and Platinum Chemoresistance of Cancer Stem-like Cells in Human Non-small Cell Lung Cancer.
    Cancer Res. 2017 Apr 17. pii: canres.1633.2016.
    PubMed     Text format     Abstract available
    
    
    
43. STEVENS LE, Cheung WKC, Adua SJ, Arnal-Estape A, et al
    Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases.
    Cancer Res. 2017;77:1905-1917.
    PubMed     Text format     Abstract available
    
    
    
44. WEN H, Chiu YF, Kuo MH, Lee KL, et al
    Expression of neuroendocrine factor VGF in lung cancer cells confers resistance to EGFR kinase inhibitors and triggers epithelial-to-mesenchymal transition.
    Cancer Res. 2017 Apr 5. pii: canres.3168.2016.
    PubMed     Text format     Abstract available
    
    
    
45. WALTER DM, Venancio OS, Buza EL, Tobias JW, et al
    Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma.
    Cancer Res. 2017;77:1719-1729.
    PubMed     Text format     Abstract available
    
    
    March 2017
46. LIAO L, Song M, Li X, Tang L, et al
    E3 ubiquitin ligase UBR5 drives the growth and metastasis of triple negative breast cancer.
    Cancer Res. 2017 Mar 22. pii: canres.2409.2016.
    PubMed     Text format     Abstract available
    
    
    February 2017
47. WANG M, Han J, Marcar L, Black J, et al
    Radiation resistance in KRAS-mutated lung cancer is enabled by stem-like properties mediated by an osteopontin-EGFR pathway.
    Cancer Res. 2017 Feb 15. pii: canres.0808.2016.
    PubMed     Text format     Abstract available
    
    
    
48. ZHANG Y, Wei Y, Jiang B, Chen L, et al
    Scavenger receptor A1 prevents metastasis of non-small cell lung cancer via suppression of macrophage serum amyloid A1.
    Cancer Res. 2017 Feb 15. pii: canres.1569.2016.
    PubMed     Text format     Abstract available
    
    
    
49. KAREKLA E, Liao WJ, Sharp B, Pugh J, et al
    Ex vivo explant cultures of non-small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy.
    Cancer Res. 2017 Feb 15. pii: canres.1121.2016.
    PubMed     Text format     Abstract available
    
    
    
50. NUKAGA S, Yasuda H, Tsuchihara K, Hamamoto J, et al
    Amplification of EGFR wild type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors.
    Cancer Res. 2017 Feb 15. pii: canres.2359.2016.
    PubMed     Text format     Abstract available
    
    
    January 2017
51. HAN SY, Ko A, Kitano H, Choi CH, et al
    Molecular Chaperone HSP90 Is Necessary to Prevent Cellular Senescence via Lysosomal Degradation of p14ARF.
    Cancer Res. 2017;77:343-354.
    PubMed     Text format     Abstract available
    
    
    
52. KYUNG RHO J, Young Lee I, Jung Choi Y, Choi CM, et al
    Superior efficacy and selectivity of novel small molecule kinase inhibitors of T790M mutant EGFR in preclinical models of lung cancer.
    Cancer Res. 2017 Jan 12. pii: canres.2432.2016.
    PubMed     Text format     Abstract available
    
    
    
53. KAUFMAN JM, Yamada T, Park K, Timmers CD, et al
    A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.
    Cancer Res. 2017;77:153-163.
    PubMed     Text format     Abstract available
    
    
    
54. ZHOU X, Updegraff BL, Guo Y, Peyton M, et al
    PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.
    Cancer Res. 2017;77:187-197.
    PubMed     Text format     Abstract available
    
    
    
55. MAMAN S, Sagi-Assif O, Yuan W, Ginat R, et al
    The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis.
    Cancer Res. 2017;77:14-26.
    PubMed     Text format     Abstract available
    
    
    December 2016
56. TASSI E, Grazia G, Vegetti C, Bersani I, et al
    Early effector T lymphocytes coexpress multiple inhibitory receptors in primary non-small cell lung cancer.
    Cancer Res. 2016 Dec 15. pii: canres.1387.2016.
    PubMed     Text format     Abstract available
    
    
    
57. UDYAVAR AR, Wooten DJ, Hoeksema MD, Bansal M, et al
    Novel hybrid phenotype revealed in Small Cell Lung Cancer by a transcription factor network model that can explain tumor heterogeneity.
    Cancer Res. 2016 Dec 8. pii: canres.1467.2016.
    PubMed     Text format     Abstract available
    
    
    November 2016
58. DOWER CM, Bhat N, Wang EW, Wang HG, et al
    Selective Reversible Inhibition of Autophagy in Hypoxic Breast Cancer Cells Promotes Pulmonary Metastasis.
    Cancer Res. 2016 Nov 15. doi: 10.1158/0008-5472.CAN-15-3458.
    PubMed     Text format     Abstract available
    
    
    
59. PAIDI SK, Rizwan A, Zheng C, Cheng M, et al
    Label-Free Raman Spectroscopy Detects Stromal Adaptations in Premetastatic Lungs Primed by Breast Cancer.
    Cancer Res. 2016 Nov 15. doi: 10.1158/0008-5472.CAN-16-1862.
    PubMed     Text format     Abstract available
    
    
    October 2016
60. SCHELHAAS S, Held A, Wachsmuth L, Hermann S, et al
    Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer.
    Cancer Res. 2016 Oct 26. pii: canres.1479.2016.
    PubMed     Text format     Abstract available
    
    
    September 2016
61. UM SW, Joung JG, Lee H, Kim H, et al
    Molecular evolution patterns in metastatic lymph nodes reflect the differential treatment response of advanced primary lung cancer.
    Cancer Res. 2016 Sep 13. pii: canres.0873.2016.
    PubMed     Text format     Abstract available
    
    
    August 2016
62. BAGHDADI M, Wada H, Nakanishi S, Abe H, et al
    Chemotherapy-induced IL-34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells.
    Cancer Res. 2016 Aug 22. pii: canres.1170.2016.
    PubMed     Text format     Abstract available
    
    
    
63. YASUFUKU K, Jin CS, Wada H, Anayama T, et al
    An integrated nanotechnology-enabled transbronchial image-guided intervention strategy for peripheral lung cancer.
    Cancer Res. 2016 Aug 19. pii: canres.3196.2015.
    PubMed     Text format     Abstract available
    
    
    
64. PATEL YM, Park SL, Han Y, Wilkens LR, et al
    Novel Association of Genetic Markers Affecting CYP2A6 activity and Lung Cancer Risk.
    Cancer Res. 2016 Aug 3. pii: canres.0446.2016.
    PubMed     Text format     Abstract available
    
    
    
65. YOLDI G, Pellegrini P, Trinidad EM, Cordero A, et al
    RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation.
    Cancer Res. 2016 Aug 1. pii: canres.2745.2015.
    PubMed     Text format     Abstract available
    
    
    June 2016
66. HALL Z, Ament Z, Wilson CH, Burkhart DL, et al
    Myc expression drives aberrant lipid metabolism in lung cancer.
    Cancer Res. 2016 Jun 22. pii: canres.3403.2015.
    PubMed     Text format     Abstract available
    
    
    
67. OH AY, Jung YS, Kim J, Lee JH, et al
    Inhibiting DX2-p14/ARF interaction exerts antitumor effects in lung cancer and delays tumor progression.
    Cancer Res. 2016 Jun 14. pii: canres.1025.2015.
    PubMed     Text format     Abstract available
    
    
    
68. CHALLA S, Guo J, Ding X, Xu CX, et al
    IKBKE is a substrate of EGFR and a therapeutic target in non-small cell lung cancer with activating mutations of EGFR.
    Cancer Res. 2016 Jun 10. pii: canres.0069.2016.
    PubMed     Text format     Abstract available
    
    
    May 2016
69. MARWITZ S, Depner S, Dvornikov D, Merkle R, et al
    Downregulation of the TGF-beta pseudoreceptor BAMBI in non-small cell lung cancer enhances TGF-beta signaling and invasion.
    Cancer Res. 2016 May 17. pii: canres.1326.2015.
    PubMed     Text format     Abstract available
    
    
    April 2016
70. CAETANO MS, Zhang H, Cumpian AM, Gong L, et al
    IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available
    
    
    
71. BOUTET M, Gauthier L, Leclerc M, Gros G, et al
    TGFbeta Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment.
    Cancer Res. 2016;76:1757-69.
    PubMed     Text format     Abstract available
    
    
    
72. FUCIKOVA J, Becht E, Iribarren K, Goc J, et al
    Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.
    Cancer Res. 2016;76:1746-56.
    PubMed     Text format     Abstract available
    
    
    March 2016
73. LIU Y, Amin EB, Mayo MW, Chudgar NP, et al
    CK2alpha' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation.
    Cancer Res. 2016 Mar 15. pii: canres.2888.2015.
    PubMed     Text format     Abstract available
    
    
    
74. BOUILLEZ A, Rajabi H, Pitroda S, Jin C, et al
    Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.
    Cancer Res. 2016;76:1538-48.
    PubMed     Text format     Abstract available
    
    
    
75. JOHNSON N, De Ieso P, Migliorini G, Orr N, et al
    Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available
    
    
    
76. KOYAMA S, Akbay EA, Li YY, Aref AR, et al
    STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
    Cancer Res. 2016;76:999-1008.
    PubMed     Text format     Abstract available
    
    
    
77. CHOI SH, Nam JK, Kim BY, Jang J, et al
    HSPB1 Inhibits the Endothelial-to-Mesenchymal Transition to Suppress Pulmonary Fibrosis and Lung Tumorigenesis.
    Cancer Res. 2016;76:1019-30.
    PubMed     Text format     Abstract available
    
    
    February 2016
78. BROOKS GD, McLeod L, Alhayyani S, Miller A, et al
    IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis.
    Cancer Res. 2016;76:866-76.
    PubMed     Text format     Abstract available
    
    
    
79. MURAYAMA T, Nakaoku T, Enari M, Nishimura T, et al
    Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available
    
    
    
80. FUJITA H, Nagakawa K, Kobuchi H, Ogino T, et al
    Phytoestrogen suppresses efflux of the diagnostic marker protoporphyrin IX (PpIX) in lung carcinoma.
    Cancer Res. 2016 Feb 2. pii: canres.1484.2015.
    PubMed     Text format     Abstract available
    
    
    
81. BRENTVILLE VA, Metheringham RL, Gunn B, Symonds P, et al
    Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity.
    Cancer Res. 2016;76:548-60.
    PubMed     Text format     Abstract available
    
    
    
82. LI M, Kales SC, Ma K, Shoemaker BA, et al
    Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.
    Cancer Res. 2016;76:561-71.
    PubMed     Text format     Abstract available
    
    
    January 2016
83. JIA Y, Juarez J, Li J, Manuia M, et al
    EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor.
    Cancer Res. 2016 Jan 29. pii: canres.2581.2015.
    PubMed     Text format     Abstract available
    
    
    
84. YAN J, Ojo D, Kapoor A, Lin X, et al
    Neural cell adhesion protein CNTN1 promotes the metastatic progression of prostate cancer.
    Cancer Res. 2016 Jan 21. pii: canres.1898.2015.
    PubMed     Text format     Abstract available
    
    
    
85. OHAR JA, Cheung M, Talarchek J, Howard SE, et al
    Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
    Cancer Res. 2016;76:206-15.
    PubMed     Text format     Abstract available
    
    
    
86. DE RIENZO A, Archer MA, Yeap BY, Dao N, et al
    Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
    Cancer Res. 2016;76:319-28.
    PubMed     Text format     Abstract available
    
    
    
87. MEIER C, Hardtstock P, Joost S, Alla V, et al
    p73 and IGF1R Regulate Emergence of Aggressive Cancer Stem-like Features via miR-885-5p Control.
    Cancer Res. 2016;76:197-205.
    PubMed     Text format     Abstract available
    
    
    
88. DUBOIS F, Keller M, Calvayrac O, Soncin F, et al
    RASSF1A suppresses the invasion and metastatic potential of human non-small cell lung cancer cells by inhibiting YAP activation through the GEF-H1/RhoB pathway.
    Cancer Res. 2016 Jan 12. pii: canres.1008.2015.
    PubMed     Text format     Abstract available
    
    
    
89. AMATO KR, Wang S, Tan L, Hastings AK, et al
    EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available
    
    
    December 2015
90. ISOZAKI H, Ichihara E, Takigawa N, Ohashi K, et al
    Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases.
    Cancer Res. 2015 Dec 30. pii: canres.1010.2015.
    PubMed     Text format     Abstract available
    
    
    
91. RIQUELME E, Behrens C, Lin HY, Simon GR, et al
    Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations.
    Cancer Res. 2015 Dec 16. pii: canres.1141.2015.
    PubMed     Text format     Abstract available
    
    
    
92. LASTWIKA KJ, Wilson W 3rd, Li QK, Norris J, et al
    Control of PD-L1 expression by oncogenic activation of the AKT/mTOR pathway in non-small cell lung cancer.
    Cancer Res. 2015 Dec 4. pii: canres.3362.2014.
    PubMed     Text format     Abstract available
    
    
    November 2015
93. MOMCILOVIC M, McMickle R, Abt E, Seki A, et al
    Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.
    Cancer Res. 2015;75:4910-22.
    PubMed     Text format     Abstract available
    
    
    
94. LANZARDO S, Conti L, Rooke R, Ruiu R, et al
    Immunotargeting of antigen xCT attenuates stem-like cell behavior and metastatic progression in breast cancer.
    Cancer Res. 2015 Nov 13. pii: canres.1208.2015.
    PubMed     Text format     Abstract available
    
    
    
95. CHOI JW, Kim JK, Yang YJ, Kim P, et al
    Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells.
    Cancer Res. 2015;75:4474-82.
    PubMed     Text format     Abstract available
    
    
    
96. ZHANG W, Gao Y, Li F, Tong X, et al
    YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin.
    Cancer Res. 2015;75:4450-7.
    PubMed     Text format     Abstract available
    
    
    
97. ELKIN SR, Bendris N, Reis CR, Zhou Y, et al
    A systematic analysis reveals heterogeneous changes in the endocytic activities of cancer cells.
    Cancer Res. 2015;75:4640-50.
    PubMed     Text format     Abstract available
    
    
    October 2015
98. HAM B, Wang N, D'Costa Z, Fernandez MC, et al
    TNF receptor-2 facilitates an immunosuppressive microenvironment in the liver to promote the colonization and growth of hepatic metastases.
    Cancer Res. 2015 Oct 19. pii: canres.3173.2014.
    PubMed     Text format     Abstract available
    
    
    
99. SOUCHERAY M, Capelletti M, Pulido I, Kuang Y, et al
    Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
    Cancer Res. 2015;75:4372-83.
    PubMed     Text format     Abstract available
    
    
    
100. YAMADA T, Amann JM, Fukuda K, Takeuchi S, et al
     Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.
     Cancer Res. 2015;75:4188-97.
     PubMed     Text format     Abstract available
     
     
     September 2015
101. JACOB LS, Vanharanta S, Obenauf AC, Pirun M, et al
     Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations.
     Cancer Res. 2015;75:3713-9.
     PubMed     Text format     Abstract available
     
     
     
102. VANGAMUDI B, Paul TA, Shah PK, Kost-Alimova M, et al
     The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
     Cancer Res. 2015;75:3865-78.
     PubMed     Text format     Abstract available
     
     
     
103. GUO G, Gong K, Wohlfeld B, Hatanpaa KJ, et al
     Ligand-Independent EGFR Signaling.
     Cancer Res. 2015;75:3436-41.
     PubMed     Text format     Abstract available
     
     
     August 2015
104. ZHANG Q, Qin J, Zhong L, Gong L, et al
     CCL5-mediated Th2 immune polarization promotes metastasis in luminal breast cancer.
     Cancer Res. 2015 Aug 6. pii: canres.3590.2014.
     PubMed     Text format     Abstract available
     
     
     June 2015
105. KAPOOR V, Khudanyan A, de la Puente P, Campian J, et al
     Stem cell transfusion restores immune function in radiation-induced lymphopenic C57/BL6 mice.
     Cancer Res. 2015 Jun 30. pii: canres.1412.2015.
     PubMed     Text format     Abstract available
     
     
     
106. CHANG YW, Su YJ, Hsiao M, Wei KC, et al
     Diverse Targets of beta-catenin during the Epithelial-Mesenchymal Transition Define Cancer Stem Cells and Predict Disease Relapse.
     Cancer Res. 2015 Jun 29. pii: canres.3265.2014.
     PubMed     Text format     Abstract available
     
     
     April 2015
107. BONASTRE E, Verdura S, Zondervan I, Facchinetti F, et al
     PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion.
     Cancer Res. 2015;75:1287-97.
     PubMed     Text format     Abstract available
     
     
     
108. RICE WL, Shcherbakova DM, Verkhusha VV, Kumar AT, et al
     In vivo tomographic imaging of deep-seated cancer using fluorescence lifetime contrast.
     Cancer Res. 2015;75:1236-43.
     PubMed     Text format     Abstract available
     
     
     February 2015
109. JIANG F, Chen L, Yang YC, Wang XM, et al
     CYP3A5 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Regulating mTORC2/Akt Signaling.
     Cancer Res. 2015 Feb 3. pii: canres.1589.2014.
     PubMed     Text format     Abstract available
     
     
     January 2015
110. YU J, Wang Y, Liu C, Luo M, et al
     Chemotherapy-induced miRNA-29c/catenin-delta signaling suppresses metastasis in gastric cancer.
     Cancer Res. 2015 Jan 29. pii: canres.0787.2014.
     PubMed     Text format     Abstract available
     
     
     
111. NESKEY DM, Osman AA, Ow TJ, Katsonis P, et al
     Evolutionary Action score of TP53 (EAp53) identifies high risk mutations associated with decreased survival and increased distant metastases in head and neck cancer.
     Cancer Res. 2015 Jan 29. pii: canres.2735.2014.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: